Veradermics reports Q3 2026 results, $798.4 million cash, runway into 2030
Company says cash funds operations into 2030 through multiple Phase 3 readouts and potential launch of VDPHL01, with female pattern hair loss data due in 1H27.
Veradermics, Incorporated reported third-quarter 2026 financial results on November 10, 2026, alongside updates on its oral minoxidil candidate VDPHL01 for pattern hair loss.
The company said positive topline results from Phase 3 Study '304' and positive 12-month data from Phase 2/3 Study '302' position VDPHL01 to potentially become the first oral treatment to receive FDA approval for pattern hair loss in nearly 30 years.1 It also said it remains on track to deliver topline data from Phase 2/3 Study '306' evaluating VDPHL01 in female pattern hair loss in 1H27.1
In men, Study '302' and Study '304' collectively enrolled more than 1,000 male participants and demonstrated early, consistent, and robust hair growth, according to the company.1 In the 12-month Study '302' data, participants in the VDPHL01 continued group who received VDPHL01 8.5 mg twice (BID) or once (QD) daily for twelve months achieved a mean increase in non-vellus target area hair count of 43.9 hairs/cm² (BID) and 29.7 hairs/cm² (QD) at Month 12.1 Treatment was generally well tolerated through Month 12, with an overall safety profile consistent with Part A of Study '302' and Study '304', no treatment-related serious adverse events, no cardiac-related adverse events of special interest, and no new safety signals.1
In women, the company announced positive topline results in July 2026 from open-label Study '207' and completed enrollment in August 2026 for the registration-directed Phase 2/3 Study '306', the first such trial of an oral therapy specifically for women with pattern hair loss in the U.S.1 The company expects to report topline data from Study '306' in the first half of 2027.1
On financials, cash, cash equivalents, and marketable securities totaled $798.4 million as of September 30, 2026.1 Net loss was $21.0 million for the third quarter of 2026, compared to a net loss of $20.1 million for the third quarter of 2025.1 The company said its cash position is expected to fund operations into 2030 through multiple Phase 3 readouts and potential commercial launch of VDPHL01.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.